Its shares falling by -13.1% today, Viatris seems to be confirming what most analysts are saying about the stock. Despite its average rating of hold, might the stock be attractive to long term value investors? Let's unpack some of the company's fundamentals to find out.
Over the last year, Viatris shares have moved -9.1% while trading between the prices of $8.77 and $13.55. This represents a -26.0% difference compared to the S&P 500, which moved 16.9% over the last 52 weeks.
At its current price of $9.77 per share, VTRS has a trailing price to earnings (P/E) ratio of -13.4 based on its 12 month trailing earnings per share of $-0.73. Considering its future earnings estimates of $2.67 per share, the stock's forward P/E ratio is 3.7. In comparison, the average P/E ratio of the Health Care sector is 26.07 and the average P/E ratio of the S&P 500 is 29.3.
We can also compare the ratio of Viatris's price to its book value. A company's book value refers to its present equity value: what is left when we subtract its liabilities from its assets. VTRS has a book value of 0.59, with anything close or below one indicating a potentially undervalued company.
A comparison of the share price versus company earnings and book value should be balanced by an analysis of the company's ability to pay its liabilities. One popular metric is the Quick Ratio, or Acid Test, which is the company's current assets minus its inventory and prepaid expenses divided by its current liabilities. Viatris's quick ratio is 0.819. Generally speaking, a quick ratio above 1 signifies that the company is able to meet its liabilities.
The final element of our analysis will touch on Viatris's capacity to generate cash for the benefit of its shareholders or for reinvesting in the business. For this, we look at the company's levered free cash flow, which is the sum of all incoming and outgoing cash flows, including the servicing of current debt and liabilities. Viatris has a free cash flow of $2.42 Billion, which it uses to pay its shareholders a 4.3% dividend.
At Market Inference, we will keep monitoring Viatris to see if the contrarian thesis in this stock will be vindicated. Going against the grain can be an excellent way for investors to extract value from the stock market, but it's never a good idea to apply a strategy for its own sake. Do your own research and make sure that the facts support your decision.
